KYTX vs LRCX · $488.8M cap vs P/E 71, rev $23.23B
Kyverna Therapeutics, Inc. Common Stock (KYTX) versus Lam Research Corp (LRCX) — a side-by-side from cached financials, not a winner call.
Kyverna Therapeutics, Inc. Common Stock (KYTX) is a biotechnology company listed on NASDAQ.
Lam Research Corp (LRCX) is a semiconductor equipment & materials company listed on NASDAQ. It is led by Timothy M. Archer.
KYTX does not have a complete income-statement cache yet.
Latest reported LRCX revenue for 2026-06-28 was $23.23B. Net income was $7.27B. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
KYTX currently screens at market cap $488.8M. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
Not investment advice. Open the KYTX and LRCX stock pages for the full models.
Not investment advice.